GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vistagen Therapeutics Inc (NAS:VTGN) » Definitions » YoY EPS Growth

VTGN (Vistagen Therapeutics) YoY EPS Growth : -109.09% (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Vistagen Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Vistagen Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2024 was -109.09%.

Vistagen Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.46.

Vistagen Therapeutics YoY EPS Growth Historical Data

The historical data trend for Vistagen Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vistagen Therapeutics YoY EPS Growth Chart

Vistagen Therapeutics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.44 2.00 49.80 -15.33 82.14

Vistagen Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.51 79.17 62.77 36.36 -109.09

Vistagen Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Vistagen Therapeutics's YoY EPS Growth for the fiscal year that ended in Mar. 2024 is calculated as:

YoY EPS Growth (A: Mar. 2024 )
=(Earnings per Share (Diluted) (A: Mar. 2024 )-Earnings per Share (Diluted) (A: Mar. 2023 ))/ | Earnings per Share (Diluted) (A: Mar. 2023 ) |
=(-1.52--8.51)/ | -8.51 |
=82.14 %

Vistagen Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EPS Growth (Q: Dec. 2024 )
=(Earnings per Share (Diluted) (Q: Dec. 2024 )-Earnings per Share (Diluted) (Q: Dec. 2023 )) / | Earnings per Share (Diluted) (Q: Dec. 2023 )) |
=(-0.46--0.22)/ | -0.22 |
=-109.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Vistagen Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Vistagen Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vistagen Therapeutics Inc (NAS:VTGN) » Definitions » YoY EPS Growth
Comparable Companies
CABA BYSI ANRO IOBT INZY CLSD MGX CBUS PYXS ABOS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
Website
https://www.vistagen.com
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Executives
Joshua S. Prince officer: Chief Operating Officer C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Cynthia Lynn Anderson officer: CHIEF FINANCIAL OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Jerry B Gin director 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Reid G. Adler officer: CHIEF LEGAL OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94090
Shawn Singh director, officer: CHIEF EXECUTIVE OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Eg, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Bong Y Koh 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Co-investment Holdings Ii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Nimish P Shah 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036